For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 20,687 | 26,281* | 18,225 | 21,491 |
| General and administrative | 7,136 | 12,856* | 6,871 | 7,093 |
| Total operating expenses | 27,823 | 39,137 | 25,096 | 28,584 |
| Loss from operations | -27,823 | -39,137* | -25,096 | -28,584 |
| Interest income | 4,196 | 3,715* | 4,948 | 3,251 |
| Change in fair value of contingent value right liability | - | 0* | 0 | 0 |
| Income tax expense | - | 0* | 0 | 0 |
| Other expense | 0 | -46* | 0 | -2 |
| Total other income (expense), net | 4,196 | 3,669* | 4,948 | 3,249 |
| Net loss | -23,627 | -35,469* | -20,148 | -25,335 |
| Net unrealized gaines on marketable securities | -716 | -76* | 398 | -161 |
| Comprehensive loss | -24,343 | -35,546 | -19,750 | -25,496 |
| Basic EPS | -0.38 | -0.637 | -0.32 | -0.49 |
| Diluted EPS | -0.38 | -0.637 | -0.32 | -0.49 |
| Basic Average Shares | 62,799,326 | 55,793,831 | 62,093,795 | 52,105,052 |
| Diluted Average Shares | 62,799,326 | 55,793,831 | 62,093,795 | 52,105,052 |
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)